Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04899570
- Locations
- ๐จ๐ณ
Peking Union Medical College Hospital, Beijing, Beijing, China
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Tavanta Therapeutics
- Target Recruit Count
- 107
- Registration Number
- NCT04887506
- Locations
- ๐ฌ๐ง
Research Site, London, United Kingdom
Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04882683
- Locations
- ๐จ๐ณ
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shandong, Shandong, China
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 174
- Registration Number
- NCT04884035
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
๐ฆ๐บLocal Institution - 501, Adelaide, South Australia, Australia
๐ต๐ฑUniwersyteckie Centrum Kliniczne, Gdansk, Poland
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04872790
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Yazeed Sawalha
- Target Recruit Count
- 24
- Registration Number
- NCT04850495
- Locations
- ๐บ๐ธ
MUSC, Charleston, South Carolina, United States
๐บ๐ธOhio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Assistance Publique - Hรดpitaux de Paris
- Target Recruit Count
- 204
- Registration Number
- NCT04844814
- Locations
- ๐ซ๐ท
Rhumathology department, Paris, Ile-De-France, France
Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2022-09-16
- Target Recruit Count
- 78
- Registration Number
- NCT04835870
- Locations
- ๐จ๐ณ
The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
๐จ๐ณNanjing Drum Tower Hospital, Nanjing, Jiangsu, China
๐จ๐ณThe First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
- Conditions
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Myrtelle Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04833907
- Locations
- ๐บ๐ธ
Dayton Children's Hospital, Dayton, Ohio, United States
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 899
- Registration Number
- NCT04824092
- Locations
- ๐จ๐ณ
Morphsys Research Site, Taoyuan, Taiwan
๐ฌ๐งMorphoSys Research Site, Wolverhampton, United Kingdom
๐ท๐บMorphosys research site, UFA, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.